Blog
Technical depth, clinical context, and the standards work happening at the intersection of precision medicine and health interoperability.
Latest Post
Researchers have identified a gene, VGLL3, that may be a root cause of preeclampsia. It's the latest example of a familiar arc — and a reminder that the benefits must reach beyond academic centers.
Read Post →More Featured
Intersect has been selected from 309 applicants nationwide for the American Heart Association's national accelerator, focused on Adoption Intelligence.
Read Post →A jargon-free explanation of FHIR (the common language of health data) and HL7 CodeX — and why they decide whether your records can follow you.
Read Post →A paper our team contributed to has been accepted by AMIA — applying GA4GH Cat-VRS and HL7 FHIR Genomics to automate complex-variant annotation.
Read Post →More Posts
Rural cancer death rates run 14% higher than urban; 5-year survival is 8% lower — and the gap is widening. Why the real divide is distance from specialty resources.
One in three rural hospitals is at risk of closure — the case for the Hub and Spoke model, and what closure really costs a community.
Six clinical solutions — cardiovascular, oncology, pain management, pharmacogenomics, chronic disease, and maternal health — all operational on a single FHIR R6-native platform.
Coming Soon
The clinical case for matching variants to individual agents — erlotinib vs. gefitinib vs. osimertinib — rather than drug classes.
Intersect joins HL7 CodeX as an invited Developer/Implementer member — active in the Molecular Tumor Board and Pathogen Genomics workgroups.
Why we chose FHIR R6 before it was finalized, and what that decision means for interoperability with Epic, Cerner, and any SMART-enabled system.